



## Acute membrane repair for deadly degenerative diseases

### Problem: Protein misfolding diseases

- **Over 50 deadly degenerative diseases** associated with protein misfolding and aggregation: Alzheimer's (AD), Parkinson's (PD), type II diabetes, ALS, Huntington's (HD), many rare diseases.
- **Enormous burden:** 540M patients requiring up to 10 years of full-time care, 3.6 million deaths per year, USD 3 trillion associated costs, USD 100B drug market, rapid growth with aging population.
- **High unmet need:** Many symptomatic treatments available, but still no safe and effective disease-modifying treatments that can stop or reverse disease progression.
- **Common mechanism:** Toxic soluble misfolded protein oligomers form annular pores that puncture holes in cell membranes, just like bacterial pore-forming toxins, causing uncontrolled calcium influx, loss of homeostasis and cellular function, oxidative stress, inflammation, progressive cell death and degeneration.

### Solution: Amporin's technology & USP

- **Amporin Pharmaceuticals AG** is developing the first breakthrough new class of oral small molecule drugs that can block, dissolve and degrade annular pores within cell and mitochondrial membranes.
- **Novel and unique mode of action:** Can uniquely protect and repair cell membranes from the damage caused by toxic soluble protein oligomers, allowing cells to fully recover and restore homeostasis.
- **USP:** First potential acute oral disease-modifying drugs to stop and reverse progression of more than 50 deadly degenerative diseases associated with protein misfolding ("golden bullet").
- **Proof of Concept:** Demonstrate complete reversal of neurological deficits with acute oral dosing in 2 established animal models.
- **Our vision:** Cure 6 major degenerative diseases with a simple pill.

### Business & development plan

- **R&D pipeline:** Targeting 6 diseases to deliver 1 new drug per year, starting with Parkinson's disease.
- **Out-licensing to Big Pharma** after rapid biomarker-based proof of disease reversal with acute oral dosing in Phase 1b/2a trials.
- **Clinical PoC:** No need for big, long and costly trials to demonstrate delay in long-term disease progression with chronic dosing.

### Company & management team

- **Incorporated:** April 2024 in Basel, Switzerland.
- **3 co-founders:** Dr Kelvin Stott (CEO), Dr Hervé Schaffhauser (CSO), Prof Daniel Umbricht MD (CMO).
- **>25 years each** in Pharma (Novartis, Roche, Merck, CSL), biotech, clinical practice, business consulting, venture capital.


### Funding & investment opportunity

- **CHF 500K raised to date:** Founders (CHF 100K equity); Venture Kick (CHF 150K loan); Kickfund (CHF 100K loan); business angels (CHF 150K loan).
- **Raising CHF 3-4M seed funding** to complete lead optimization; select and validate drug lead for PD; strengthen in vivo data & IP; start CMC & IND-enabling studies.
- **Exit by trade sale to Big Pharma:** 40-50X exit multiple by 2031.
- **Unique investment opportunity:** invest in the first potential acute oral disease-modifying drugs to cure 6 degenerative diseases.

### Contact


- **Kelvin Stott (CEO):** kelvin.stott@amporin.com; +41 78 749 49 36
- **Amporin Pharmaceuticals AG:** Tech Park, Hochbergerstrasse 60C, 4057 Basel, Switzerland.

### Social & economic cost of protein misfolding diseases




Sources: www.who.int, www.cdc.gov, www.healthdata.org, www.alz.org, www.parkinson.org, www.idf.org

### Amporin's unique approach: Targeting annular pores



### Potential for acute disease reversal with an oral drug



### Business model, development and financing plan

